Te Cardiovascular and Renal Drug Advisory Committee Meeting scheduled for February 3rd, 2009 will be webcast.
The FDA's Cardiovascular and Renal Drug Advisory Committee Meeting is being held to decide whether or not to approve a competitor drug to Plavix, the second-biggest selling drug in the world. The new drug in question is called prasugrel and would be marketed by Eli Lilly & Co with potential co-marketing by Japan's Daiichi Sankyo Co., the drug's discoverer.
Reports issued suggest that prasugrel may be more effective than Plavix in preventing heart attacks, but also a higher risk to cause dangerous bleeding. These are the issues that have been considered and will likely be commented upon as the Advisory Committee decides on approval.